당뇨병 치료제 시장 : 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global diabetes drugs market size is expected to reach USD 336.99 Billion in 2034 from USD 110.23 Billion in 2025, growing at a CAGR of 13.22 during 2026-2034.This market is experiencing substantial growth driven by the rising global prevalence of diabetes, particularly type 2 diabetes linked to sedentary lifestyles and unhealthy dietary habits. Increasing urbanization and aging populations are further contributing to the expanding patient pool. Pharmaceutical companies are focusing on developing innovative therapies, including insulin analogs, GLP-1 receptor agonists, and SGLT2 inhibitors, to improve glycemic control and reduce complications. The growing emphasis on early diagnosis and disease management is also supporting market expansion across both developed and emerging regions.

Key drivers include advancements in drug development, increasing healthcare expenditure, and improved access to treatment. The integration of digital health tools, such as glucose monitoring systems and connected insulin delivery devices, is enhancing patient compliance and treatment outcomes. Additionally, government initiatives and awareness programs are encouraging timely diagnosis and treatment. The rise of combination therapies and personalized medicine approaches is further transforming the diabetes treatment landscape, offering more effective and tailored solutions.

Future prospects for this market remain highly promising, with ongoing research into novel drug classes and regenerative therapies. The development of oral insulin and advanced biologics is expected to revolutionize treatment options. Emerging markets are likely to play a crucial role due to increasing healthcare access and rising disease awareness. As the burden of diabetes continues to grow globally, the diabetes drugs market is poised for sustained and dynamic expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Class

• Insulin
• DPP-4 Inhibitors
• GLP-1 Receptor Agonists
• SGLT2 Inhibitors
• Others

By Diabetes Type

• Type 1
• Type 2

By Route of Administration

• Oral
• Subcutaneous
• Intravenous

By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

COMPANIES PROFILED

• Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Merck & Co. Inc., AstraZeneca plc, Novartis AG, Johnson & Johnson (Janssen Pharmaceuticals), Bayer AG, Bristol Myers Squibb, Pfizer Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DIABETES DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Insulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. DPP-4 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. GLP-1 Receptor Agonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. SGLT2 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DIABETES DRUGS MARKET: BY DIABETES TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Diabetes Type
• 5.2. Type 1 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Type 2 Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DIABETES DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DIABETES DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL DIABETES DRUGS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Diabetes Type
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Diabetes Type
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Diabetes Type
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Diabetes Type
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Diabetes Type
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL DIABETES DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Novo Nordisk A/S
  • 10.2.2 Sanofi
  • 10.2.3 Eli Lilly And Company
  • 10.2.4 Merck & Co. Inc
  • 10.2.5 AstraZeneca Plc
  • 10.2.6 Novartis AG
  • 10.2.7 Johnson & Johnson (Janssen Pharmaceuticals)
  • 10.2.8 Bayer AG
  • 10.2.9 Bristol Myers Squibb
  • 10.2.10 Pfizer Inc